DURYSTA Implant

The FDA approved the DURYSTA implant in June 2020 for the treatment of open-angle glaucoma. DURYSTA.Recommendations and consent discusses the risk of endothelial cell loss (ECL), and provides a sample consent form to help educate patients about the risks and benefits. Both the recommendations and consent form address implanting more than one DURYSTA per eye.

Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Six reasons OMIC is the best choice for ophthalmologists in America.

Leader in the industry.

A-rated by AM Best, OMIC is consistently ranked among the top malpractice insurance companies in America for financial stability. No other carrier has matched OMIC's consistent financial performance with regard to both combined, operating, and surplus ratios, the most relevant financial measurements for an insurance carrier.